Strategic leadership ARTIDIS has recently appointed Julie Gerberding as President and CEO, signaling a proven leadership team with deep health, policy, and biopharma network potential. This creates opportunities to align with their strategic priorities and engage high-level sponsor discussions and partnerships.

Clinical trial momentum The ANGEL breast cancer study and ongoing multicentre trials position ARTIDIS as a clinically validated platform at the bedside. This presents openings to healthcare systems, CROs, and oncology centers looking to integrate nanomechanical tissue analysis into trial workflows and diagnostic pathways.

Hospital collaborations Existing collaborations with Hospital Clínic de Barcelona, University of Barcelona, and potential MD Anderson partnerships indicate a strong network in academic and tertiary centers. Targeted outreach to major cancer centers and university hospitals could expand study sites and real-world evidence generation.

Decentralized tech fit ARTIDIS emphasizes bedside tissue analysis and digital data solutions, leveraging cloud and containerized tech (Docker, Kubernetes, ELK, Argo CD, Azure). This suggests sales opportunities for integrated IT infrastructure, data analytics, and workflow automation within oncology labs and radiology/pathology departments seeking rapid, point-of-care insights.

Medical device adoption With a clinical-stage device and solid tumor focus, there is potential in health systems and private clinics seeking complementary diagnostics to chemotherapy, immunotherapy, and cell therapies. Position offerings around accelerated decision-making, personalized therapy optimization, and potential cost-of-care improvements.